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Abstract 
This review highlights ten important advances in the neuromuscular disease field that were first reported in 
2020. The overarching topics include (i) advances in understanding of fundamental neuromuscular biology; (ii) 
new / emerging diseases; (iii) advances in understanding of disease etiology and pathogenesis; (iv) diagnostic 
advances; and (v) therapeutic advances. Within this broad framework, the individual disease entities that are 
discussed in more detail include neuromuscular complications of COVID-19, supervillin-deficient myopathy, 
19p13.3-linked distal myopathy, vasculitic neuropathy due to eosinophilic granulomatosis with polyangiitis, 
spinal muscular atrophy, idiopathic inflammatory myopathies, and transthyretin neuropathy/myopathy. In 
addition, the review highlights several other advances (such as the revised view of the myofibrillar architecture, 
new insights into molecular and cellular mechanisms of muscle regeneration, and development of new electron 
microscopy tools) that will likely have a significant impact on the overall neuromuscular disease field going 
forward. 
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AAV, adeno-associated virus; ANCA, antineu-
trophil cytoplasmic antibody; ASM, antisynthetase 
syndrome-associated myositis; ATTR, transthyretin 
amyloidosis; CGRP, calcitonin-gene related peptide; 
COVID-19, Coronavirus Disease 2019; CK, creatine 
kinase; DM, dermatomyositis; FESEM, field-
emission scanning electron microscopy; GLUD1, 
glutamate dehydrogenase 1; EGPA, eosinophilic 
granulomatosis with polyangiitis; GBS, Guillain-
Barré syndrome(s); HMGCR, 3-hydroxy-3-
methylglutaryl-CoA reductase; IIM, idiopathic in-
flammatory myopathy; IMNM, immune-mediated 
necrotizing myopathy; LMN, lower motor neuron; 
MmSc, muscle mesenchymal stromal cells; NMD, 
neuromuscular disease; SARS, severe acute respira-
tory syndrome; sIBM, sporadic inclusion body myo-
sitis; SMA, spinal muscular atrophy; SMALED, spi-
nal muscular atrophy lower extremity dominant; 
SRP, signal recognition particle; STEM, scanning 
transmission electron microscopy; SVV, small ves-
sel vasculitis; TEM, transmission electron microsco-
py; Tregs, regulatory T cells; TTR, transthyretin. 
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In this update, I will briefly describe ten 2020 
neuromuscular field advances that I consider to be 
most important and/or interesting; as in the prior 
update (Margeta, 2020b), these advances will be 
grouped into several different “discovery clusters” 
and listed in no particular order. 
Advances in fundamental neuromus-
cular biology with implications for 
neuromuscular disease 
1. New understanding of the myofibrillar archi-
tecture 
Based on numerous studies that used tradi-
tional electron microcopy methods for evaluation 
of skeletal muscle ultrastructure, the myofibrillar 
apparatus has long been understood as consisting 
of independent tube-like myofibrils that are ar-
ranged in parallel and span the entire length of a 
fiber, with each myofibril composed of sarcomeres 
that are serially connected through Z-discs. This 
traditional model of the myofibrillar apparatus was 
effective in explaining how the contractile forces 
are transmitted down the length of the fiber to-
wards the myotendinous junction, but could not 
readily explain how these forces were transmitted 
laterally, towards the sarcolemma and the extracel-
lular matrix (into which myofibers are anchored 
through costameres, the sarcolemma-associated 
supramolecular structures that form membrane 
skeleton and mediate fiber adhesion). 
A recent groundbreaking study by Willingham 
et al. has used a new method (focused ion beam-
scanning electron microscopy) to image muscle 
fibers in three dimensions at high resolution, 
providing a new view of the myofibrillar architec-
ture (Willingham et al., 2020). To their surprise, the 
authors found that sarcomeres are not organized 
into independent parallel myofibrils as traditionally 
thought, but instead form the unified, non-linear 
myofibrillar matrix that spans both the length and 
the width of a fiber and is interconnected through 
extensive and bidirectional sarcomere branching 
(Fig. 1). This branching occurs in what appears to 
be a random pattern, with branch points that are 
not restricted to any specific region of the sarco-
mere; however, the frequency of branches is fiber-
type specific, with branches approximately three 
times more frequent in slow twitch than fast twitch 
fibers (and approximately two times more frequent 
in slow twitch fibers than cardiac myocytes). Inter-
estingly, sarcomere branching is developmentally 
regulated: while present at birth, it is downregulat-
ed in the period of rapid postnatal muscle growth 
and then upregulated again late in development. 
Three different mechanisms of sarcomere branch-
ing were identified: sarcomere splitting (where 
some of the myofilaments from one sarcomere 
separated from the rest, forming two distinct myo-
fibrillar segments), myofilament transfer (where 
some of the myofilaments were redistributed be-
tween sarcomeres, separating from one myofibril-
lar segment and joining the adjacent one) and my-
ofilament trade (where myofilament transfer be-
tween two adjacent myofibrillar segments was 
reciprocal/bilateral). While most of the work was 
performed on murine samples, the few human 
samples that were evaluated in this study showed 
essentially identical findings, except for a slightly 
higher branching frequency in human compared to 
murine fast-twitch fibers (2.4 ± 0.2 vs. 1.6 ± 0.2 
branches per 10 sarcomeres); however, a more 
thorough investigation of inter-species differences 
remains to be done. 
What is the relevance of this new understand-
ing of the myofibrillar architecture for neuromuscu-
lar disease (NMD)? That must be experimentally 
addressed and therefore remains to be seen, but it 
is very likely that abnormal branching of sarco-
meres contributes to poor contractile force genera-
tion in various congenital / structural myopathies, 
which show different degrees of organelle malposi-
tioning and myofilament disorganization. In addi-
tion, this new discovery may have important impli-
cations for pathogenesis of muscular dystrophies: 
given that the myofibrillar matrix is directly con-
nected to the costameric membrane skeleton (dis-
cussed further in advance #4 below), it is possible 
that disruption of these connections may result in 
inappropriate transfer of lateral mechanical forces 
from the interior of the fiber to the extracellular 
matrix, thereby contributing to the likelihood of 
segmental fiber necrosis that over time leads to 
exhaustion of the muscle regenerative capacity and 
muscle wasting. 
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Figure 1. 3D renderings of the interconnected sarcomeres that form the unified myofibrillar matrix. A. 3D rendering of 115 directly 
connected sarcomeres within the myofibrillar matrix of a fast-twitch muscle. Individual colors represent different myofibrillar segments 
linked by branching sarcomeres. B-D. 3D renderings at different perspectives highlight the nonlinearity and connections between myo-
fibrillar segments. Representative of 7,707 sarcomeres from four volumes from four mice. Scale bars, 2 µm. (This figure and its legend 
were adopted from Figure 1 in Willingham et al., 2020; this use is permitted under the Creative Commons Attribution 4.0 International 
License.) 
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2. Deepening insights into molecular and cellular 
mechanisms of muscle regeneration 
Over the past decade, much has been learned 
about the mechanisms of skeletal muscle regenera-
tion; the key role of satellite cells (muscle stem 
cells) in this process was first demonstrated in 
2011, and the work that followed since then has 
showed that satellite cell activation requires cyto-
kines and growth factors released by FoxP3-
expressing regulatory T cells (Tregs) and macro-
phages. Two studies published last year build fur-
ther on these discoveries by elucidating the inter-
cellular crosstalk and chemical signals that mediate 
muscle regenerative response. 
The first study focused on the interplay be-
tween intramuscular peripheral nerve twigs, mus-
cle mesenchymal stromal cells (MmSCs), and Tregs 
in skeletal muscle regeneration (Wang et al., 2020). 
Following muscle injury, MmSCs are the main 
source of interleukin (IL)-33, which drives subse-
quent accumulation of Tregs required for satellite 
cell activation and muscle repair. Wang et al. have 
found that IL-33+ MmSCs are located in close prox-
imity to peripheral nerve bundles and that they 
titrate their Il-33 production in response to calci-
tonin-gene related peptide (CGRP), which plays a 
role in pain perception and is released by sensory 
peripheral nerve terminals in response to tissue 
damage. In agreement with these findings, system-
ic administration of CGRP led to an increase in the 
muscle IL-33 level and recruitment of Tregs into the 
muscle compartment. However, it remains to be 
shown whether CGRP treatment will enhance mus-
cle regeneration and – conversely – whether inhibi-
tion of CGRP signaling will attenuate effective re-
pair following muscle injury; the latter question is 
particularly pressing given that anti-CGRP antibod-
ies and CGRP antagonists have recently been ap-
proved for prevention of migraine headaches. In 
addition, it remains to be seen whether effective 
muscle repair requires only signaling from sensory 
nerve terminals, or whether motor nerve twigs also 
play a role in this process. 
The second and more comprehensive of the 
two studies centered on the nature of chemical 
crosstalk between macrophages and satellite cells 
that is required for muscle repair (Shang et al., 
2020). The authors of that study modulated gluta-
mine secretion from macrophages via genetic or 
pharmacologic manipulation of glutamine synthe-
tase (which generates glutamine by condensation 
of glutamate and ammonia) or glutamate dehydro-
genase 1 (GLUD1, which catalyzes oxidative deami-
nation of glutamate and thereby reduces the 
amount of glutamate available for glutamine syn-
thesis); in addition, they blocked satellite cell glu-
tamine uptake by knocking down glutamine trans-
porter SLC1A5 selectively in those cells. Using these 
experimental approaches both in vitro and in vivo, 
the authors demonstrated that satellite cells take 
up glutamine that is secreted by monocyte-derived 
macrophages recruited into skeletal muscle follow-
ing injury; this glutamate uptake, which leads to 
activation of mTOR signaling, is required for satel-
lite cell proliferation and differentiation. Excitingly, 
Shang et al. showed that increased glutamine bioa-
vailability in injured or aged muscle translates into 
increased muscle regenerative capacity: mice with 
decreased GLUD1 activity showed faster and more 
effective fiber regeneration following acute myo-
toxic injury when young, as well as increased mus-
cle mass and improved baseline physical perfor-
mance when aged. While these findings need to be 
replicated in other model systems and ultimately 
human clinical trials, they hold promise not only for 
treatment of muscular dystrophies and other skele-
tal myopathies characterized by recurring muscle 
fiber necrosis, but also for treatment of the age-
associated sarcopenia that leads to significant mor-
bidity and mortality in elderly populations. 
Newly defined / emerging neuromus-
cular diseases 
3. Neuromuscular complications of COVID-19 
2020 has been dramatically shaped by the 
COVID-19 pandemic, which has affected the NMD 
field in addition to all other aspects of life. COVID-
19 is caused by infection with SARS-CoV-2, an RNA 
virus from the coronavirus family; the disease is 
asymptomatic in up to 50% of patients, but can also 
cause severe pneumonia, acute respiratory distress 
syndrome, and death. Neurologic complications of 
COVID-19 were noted very early in the pandemic 
(Mao et al., 2020) and include CNS, PNS, and skele-
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tal muscle manifestations (Cagnazzo et al., 2020); in 
this update, two forms of potential neuromuscular 
involvement [Guillain-Barré syndromes (GBS) and 
rhabdomyolysis / myopathy] will be discussed in 
more detail. 
GBS are a group of acute immune-mediated 
polyneuropathies that are characterized by ascend-
ing weakness, mild-moderate sensory abnormali-
ties, and pain; the most common subtypes include 
acute demyelinating inflammatory polyradiculo-
neuropathy, acute motor axonal neuropathy, and 
the Miller-Fischer syndrome (Dalakas, 2020). In 
approximately 70% of GBS patients, a flu-like illness 
precedes neurologic symptoms by ~1-3 weeks, and 
all subtypes of GBS show association with different 
infectious agents (both viruses and bacteria). Per-
haps not surprisingly, GBS was also documented in 
patients with COVID-19, first through case reports 
and small case series (reviewed in Caress et al., 
2020; Dalakas, 2020; De Sanctis et al., 2020) and 
later through small retrospective case-control stud-
ies, one from Italy (Filosto et al., 2020) and another 
from Spain (Fragiel et al., 2020). Based on these 
early reports, COVID-19-associated GBS was shown 
to have typical clinical characteristics, with most 
cases falling within the acute demyelinating sub-
type and showing onset of neurologic symptoms a 
median of 10-23 days after the COVID-19 diagnosis. 
The two retrospective case-control studies found 3- 
to 10-fold higher GBS incidence during the study 
period (the 2-month pandemic peak in each coun-
try) compared to the equivalent period in 2019; 
however, the conclusions were limited by relatively 
small sample sizes and a high potential for con-
founding due to selection and ascertainment bias. 
Indeed, the most comprehensive investigation of 
the potential link between GBS and COVID-19 to 
date (a combined retrospective epidemiologic and 
prospective cohort study performed in the UK and 
published at the end of 2020) found no association 
between these two conditions (Keddie et al., 2020). 
In fact, and somewhat counterintuitively, the au-
thors of that study found a decrease (rather than 
increase) in the number of GBS cases that required 
IVIg treatment during the 2-month pandemic peak 
compared to prior years; while reasons for this 
decrease are not entirely clear, one possible expla-
nation is a decrease in the number of infections 
with known GBS-triggering pathogens as a result of 
drastic public health actions that were undertaken 
to control the pandemic. In addition to a lack of 
increase in GBS incidence, Keddie et al. found no 
temporal or spatial association between COVID-19 
and GBS cases in the UK during the study period, 
further weakening the likelihood of true association 
between these two diseases. Given these contra-
dictory findings, additional studies should be done; 
however, the preponderance of current evidence 
suggests that the SARS-CoV-2 infection is not a 
major trigger of autoimmune polyneuropathy. 
What about skeletal muscle involvement in 
COVID-19? As with other flu-like illnesses, myalgias 
are a common symptom of this viral disease; how-
ever, actual skeletal muscle injury [as evidenced by 
elevated creatine kinase (CK) levels] is seen only in 
a subset (~10-30%) of patients (Dalakas, 2020; 
Manzano et al., 2020). In some of these “COVID-19 
myopathy” cases, muscle injury is very severe, with 
CK levels greater than 10,000 U/L (Buckholz et al., 
2020; Dalakas, 2020; and a number of individual 
case reports); the most severe case was document-
ed in a patient on rosuvastatin therapy who was 
infected with SARS-CoV-2 and developed fatal 
rhabdomyolysis, with the CK level of ~1,000,000 
U/L (Anklesaria et al., 2020). However, very few 
muscle biopsies or autopsy muscle samples from 
COVID-19 patients have been comprehensively 
evaluated to date; as a result, very little is known 
about the mechanisms that underlie COVID 19-
associated muscle injury. 
Skeletal muscle expresses angiotensin-
converting enzyme 2, which serves as the cellular 
receptor for SARS-CoV-2 (Ferrandi et al., 2020); 
thus, it is conceivable that this virus can invade and 
directly injure muscle fibers. However, limited stud-
ies published thus far have not provided evidence 
for viral presence in the injured muscle (Manzano 
et al., 2020; Rosato et al., 2020; Zhang et al., 2020). 
[One case report noted the presence of corona-
virus-like particles in a postmortem muscle sample 
from a patient who died from COVID-19 but had no 
symptoms of skeletal muscle injury (Hooper et al., 
2020); however, ultrastructural detection of coro-
naviruses can be challenging (Dittmayer et al., 
2020a) and the virus-like particles shown in that 
paper more closely resemble clathrin-coated vesi-
cles or parts of the rough endoplasmic reticulum 
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than true coronaviruses.] Instead, the currently 
available data suggest that COVID 19-associated 
muscle injury is most likely para-infectious / im-
mune-mediated, and can manifest as dermatomyo-
sitis-like “type I interferonopathy” (Manzano et al., 
2020), myositis (Zhang et al., 2020), or immune-
mediated necrotizing myopathy (Fig. 2). This is in 
agreement with the work done during the SARS 
epidemic in early 2000s, which suggested that vas-
culitis or immune-mediated mechanisms, rather 
than direct viral infection, were a cause of SARS-
associated myopathy (Ding et al., 2003; Leung et 
al., 2005). Given that the available studies are very 
limited in scope, much additional work is needed to 
fully elucidate the mechanisms of skeletal muscle 
injury in COVID-19. However, an intriguing possibil-
ity is that both mechanisms play a role, as recently 
shown for the chikungunya infection-associated 
myopathy: in that emerging viral disease, muscle 
pathology is due to activation of the host immune 
response but is triggered by viral replication in 
muscle fibers (Lentscher et al., 2020). 
 
 
Figure 2. Immune-mediated necrotizing myopathy in a patient with COVID-19. A representative H&E-stained cryosection (A) shows 
frequent, randomly distributed degenerating/regenerating muscle fibers and focal myophagocytosis in the absence of a significant 
lymphocytic inflammatory infiltrate; unusual dystrophic calcifications are seen in a subset of necrotic fibers (arrows), confirmed by von 
Kossa calcium stain (not shown). Deposition of the complement membrane attack complex (C5b9-immunostained cryosection; B) is 
seen in the sarcoplasm of necrotic fibers as well as the sarcolemma of many intact-appearing fibers. Immunohistochemical stains for 
LC3 (C) and p62 (D; both performed on formalin-fixed, paraffin embedded tissue) show frequent fibers with densely packed fine puncta. 
Immunohistochemical stain for SARS-CoV-2 was negative and no coronavirus particles were detected on ultrastructural evaluation (not 
shown). The patient had a history of hepatitis C, diabetes mellitus, hypertension, and hyperlipidemia treated with atorvastatin. He was 
diagnosed with COVID-19 based on a positive SARS-CoV-2 PCR test performed following a close exposure; he was asymptomatic at the 
time, but subsequently developed progressive lower extremity weakness and dysphagia. Approximately 1 month after the first weak-
ness symptoms, he lost his sense of smell, developed shortness of breath, and was hospitalized. At admission, his CK level was 33,000 
U/L and he was still positive for SARS-CoV-2; muscle biopsy was performed 10 days into his hospital course (~ 2 months following initial 
COVID-19 diagnosis). The patient was ultimately treated with prednisone, which led to improvement of his neuromuscular symptoms; 
he was discharged from the hospital never requiring mechanical ventilation for his COVID-19 pneumonia. Testing for anti-HMGCR and 
anti-SRP antibodies was not performed. Scale bar, 50 µm. 
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4. Structural myopathy caused by supervillin 
deficiency 
The presence of occasional lobulated fibers is 
a relatively common and therefore nonspecific 
finding in muscle biopsies. In some cases, however, 
frequent lobulated fibers dominate the overall his-
topathologic picture, resulting in a descriptive di-
agnosis of a “lobular” (or “trabecular”) myopathy. 
In general, this descriptive diagnosis does not cor-
respond to a specific, well-defined clinicopathologic 
entity; however, a newly defined structural myopa-
thy caused by loss-of-function mutations in super-
villin (Hedberg-Oldfors et al., 2020) is an exciting 
exception to this rule and, while probably rare, 
should be on the radar screen of every neuromus-
cular pathologist going forward. 
Supervillin is a large, differentially spliced and 
ubiquitously expressed actin-binding protein that is 
particularly abundant in striated muscle; the 250 
kDa muscle isoform (also called archvillin) interacts 
and/or co-localizes with costameric proteins such 
as dystrophin and dystrophin-associated proteins, 
integrin/vinculin/talin complex, α-actinin, desmin, 
and caveolin 3 (Oh et al., 2003). (As mentioned in 
advance #1, costameres are membrane-associated 
supramolecular structures that mediate muscle 
fiber adhesion to the extracellular matrix.) During 
skeletal muscle development, supervillin is located 
at the ends of differentiating myotubes, where it is 
thought to contribute to the myotendinous junc-
tion formation (Oh et al., 2003). In addition, super-
villin plays a role in the myofibril assembly (Lee et 
al., 2007) and helps anchor peripheral myofibrils to 
the sarcolemma by connecting a Z-disc protein 
nebulin to costameric proteins dystrophin and γ-
sarcoglycan (Lee et al., 2008; Spinazzola et al., 
2015). (Highlighting the critical importance of myo-
fibril anchoring, Z-discs of peripheral myofibrils are 
also linked to the sarcolemma through binding of a 
Z-disc protein filamin C to costameric proteins γ-
sarcoglycan and integrin; reviewed in Peter et al., 
2011.) Mutations in genes that encode costameric 
proteins mostly lead to muscular dystrophies, while 
mutations in myofibrillar and cytoskeletal proteins 
generally result in congenital myopathies; loss-of-
function mutations in supervillin, which have previ-
ously not been associated with any muscle disease, 
are now known to cause a unique structural myo-
pathy (Hedberg-Oldfors et al., 2020). 
The authors described four patients from two 
unrelated consanguineous families (two affected 
siblings in each family) that were ultimately shown 
to carry homozygous truncating mutations in su-
pervillin, resulting in a complete loss of supervillin 
protein. While there were subtle clinical differences 
between these two families, shared clinical findings 
included onset in childhood/adolescence, muscle 
pain and stiffness without significant muscle weak-
ness, wide neck and hypertrophy of back muscles, 
progressive contractures, moderately elevated CK 
levels, and mild cardiac involvement (mainly left 
ventricular hypertrophy). Muscle biopsies from all 
four patients showed frequent lobulated type 1 
fibers, myofibrillar disarray (including occasional Z-
band streaming and nemaline rods), subsarcolem-
mal protein aggregates, and autophagic vacuoles 
(Fig. 3; see also Hedberg-Oldfors et al., 2020). Aside 
from frequent lobulated fibers, these histopatho-
logic features show some overlap with myofibrillar 
myopathies, a group of muscle disorders character-
ized by Z-disc instability and defects in the chaper-
one-assisted selective autophagy (reviewed in 
Margeta, 2020a); this histopathologic overlap may 
reflect the role of supervillin in the Z-disc stabiliza-
tion / sarcomere anchoring. Interestingly, the cur-
rently known supervillin mutations are expected to 
abolish expression of all five supervillin isoforms 
(not just the archvillin isoform expressed in striated 
muscle); while these four patients did not show 
clinical involvement of any non-muscle tissues, the 
disease spectrum is likely to widen as additional 
patients (and mutations) are identified in the fu-
ture. Going forward, it will be particularly interest-
ing to elucidate how the loss of supervillin leads to 
fiber lobulation and to establish whether similar 
mechanisms operate in other myopathies with 
frequent lobulated fibers. 
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Figure 3. Histopathology of “supervillinopathy”. Biopsy from the deltoid muscle of Patient III:2 in Family 2, as visualized by light (A–C) 
and electron microscopy (D–G). A. A considerable number of partially atrophic lobulated muscle fibers with pointed, occasionally cap-
like subsarcolemmal deposits (arrows) (H&E). B. Prominent oxidative enzyme activity in these fibers (arrows) (NADH). C. Atrophic lobu-
lated fibers are almost exclusively type 1 fibers (arrows); no neurogenic pattern is observed (mATPase at pH 9.4). D. Subsarcolemmal 
accumulation of degraded myofibrils, glycogen, pleomorphic material and autophagy-associated (arrows) organelles. E. Heterogeneous 
lipoprotein deposits including maturing lipofuscin (arrows). F. Sporadically, nemaline rods are seen (arrow). G. Three rods in transverse 
section (arrows). (This figure and its legend were adopted from Figure 5 in Hedberg-Oldfors et al., 2020; this use is permitted under the 
Creative Commons Attribution 4.0 International License.) 
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Advances in understanding of etiology 
and pathogenesis of neuromuscular 
diseases 
5. Genetic vacuolar myopathies: Expanding eti-
ology spectrum 
Vacuolar myopathies are pathologically de-
fined by the presence of autophagic vacuoles that 
can be seen on the light microscopic level (“rimmed 
vacuoles”), electron microscopic level, or both. 
Vacuolar myopathies have varied etiologies that 
include myotoxic drugs, chronic inflammation, and 
genetic mutations; genetic forms can occur either 
as stand-alone myopathies or together with amyo-
trophic lateral sclerosis, frontotemporal lobar de-
generation, and/or Paget’s disease of the bone as a 
component of multiple system proteinopathies 
(reviewed in Margeta, 2020a). Unsurprisingly, then, 
the differential diagnosis of a vacuolar myopathy 
remains broad, and the final diagnosis can be diffi-
cult to establish even in the era of widely available 
genetic testing; this complexity was highlighted by 
a 2020 study (Mair et al., 2020) that performed 
thorough clinicopathologic and genetic evaluation 
of 32 adult vacuolar myopathy cases from 30 unre-
lated families, and which includes a very compre-
hensive table of non-inflammatory causes that will 
be a useful resource for every practicing muscle 
pathologist. 
However, and highlighting the rapid pace of 
advancement in the NMD field, this table is already 
incomplete: a very exciting work published last year 
(Ruggieri et al., 2020) demonstrated that a repeat 
expansion in the lipid droplet-coating protein peril-
ipin 4 is the cause of another rimmed vacuolar my-
opathy - the autosomal dominant distal myopathy 
that was previously linked to chromosome 19p13.3 
(Di Blasi et al., 2004). The age at diagnosis in the 
originally published kindred of 19 individuals varied 
from 26 to 73 years, but was earlier in the later 
generations; the symptoms were variable, but nev-
er included dysphagia or dysphonia. Pathologically, 
the biopsies showed some unique features: vacu-
oles were mainly subsarcolemmal, membrane-
limited, and sometimes connected to the cell sur-
face and/or bordered by the basal lamina, but did 
not include filamentous inclusions and were not 
Congo red- or thioflavin S-positive (Fig. 4; see also 
Di Blasi et al., 2004; Ruggieri et al., 2020). In spite 
of early genetic linkage of this disease to chromo-
some 19p, the causative mutation proved challeng-
ing to elucidate; ultimately, Ruggieri et al. honed in 
on the correct target by performing quantitative 
mass spectroscopy of microdissected vacuoles, 
which identified perilipin 4 as the most enriched 
among 700 identified proteins. The subsequent 
analysis showed that the gene encoding perilipin 4, 
PLIN4, maps to 19p13.3; in affected patients, this 
gene contains a 891-nucelotide expansion of the 
repetitive nucleotide sequence in exon 4, resulting 
in extra 297 amino acids in the amphipathic domain 
of perilipin 4 protein. 
Perilipins are proteins that localize to the sur-
face of lipid droplets, where they interact with lipid 
enzymes and other regulators of lipid droplet me-
tabolism; the five known isoforms all contain an 11-
mer repeat sequence that repeats 3 times to form 
a 33-mer amphipathic helix required for lipid drop-
let localization (Copic et al., 2018). Perilipin 4 [the 
isoform most highly expressed in skeletal muscle, 
where it mainly localizes to the subsarcolemmal 
regions of type 1 fibers (Pourteymour et al., 2015)] 
has a very long amphipathic domain that normally 
consists of 29-31 33-mer repeats but is extended by 
9 additional 33-mers in patients with 19p13.3 distal 
myopathy (Ruggieri et al., 2020). It is currently not 
understood how this expansion of the perilipin 4 
amphipathic domain leads to muscle disease; how-
ever, the defect almost certainly does not involve 
metabolism of lipid droplets, which were similar in 
size and number in control and patient samples 
(Ruggieri et al., 2020). On the other hand, the pa-
tient samples showed an increase in subsarcolem-
mal perilipin 4 expression and co-localization of this 
protein with p62/SQSTM1, NBR1 and WDFY3 [au-
tophagic adapters that play a key role in ag-
grephagy and granulophagy (selective autophagy of 
protein aggregates and stress granules, respective-
ly)]. This finding provides a potential link between 
19p13.3 distal myopathy and multiple system pro-
teinopathies, which all show a defect in granuloph-
agy (reviewed in Margeta, 2020a). Interestingly, 
expression of perilipin 4 in the CNS is regulated by a 
stress granule RNA-binding protein TIA1 (Heck et 
al., 2014), the gain-of-function mutations in which 
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Figure 4. Histopathology of “perilipinopathy” (19p13.3-linked distal myopathy). A-B. Gomori trichrome and H&E staining, respectively, 
in patients IV:3 and V:3, showing vacuoles (arrows) [rimmed, empty, or containing granular or basophilic material (arrowheads), mainly 
located in the subsarcolemmal region of fibers], fiber size variability, central nuclei, and mildly increased endomysial spaces. Note mini-
mal changes in V:13. C. Electron micrographs unveiling vacuoles located in the subsarcolemmal region or deep in the sarcoplasm, con-
taining small vesicles, membranous bodies, and granular debris; inset shows granular debris within a small subsarcolemmal vacuole 
(arrow) opening to the fiber’s surface and sarcolemmal interruption (arrowheads). (This figure and its legend were adopted from Figure 
1 in Ruggieri et al., 2020; this use is permitted under the Creative Commons Attribution 4.0 International License.) 
 
 
lead to Welander distal myopathy (Hackman et al., 
2013; Klar et al., 2013). It remains to be shown 
whether TIA1 also regulates perilipin 4 expression 
in skeletal muscle and whether this regulation plays 
a role in pathogenesis of these two (and potentially 
other) distal vacuolar myopathies. 
6. Vasculitic neuropathy secondary to eosino-
philic granulomatosis with polyangiitis: Two 
pathogenetic mechanisms 
Vasculitic neuropathy, the most common indi-
cation for nerve biopsy in the current neuromuscu-
lar pathology practice, can be secondary to many 
different forms of vasculitis. Based on the most 
recent consensus nomenclature (Jennette et al., 
2013), small vessel vasculitis (SVV; the category of 
vasculitis that is most likely to involve peripheral 
nerves) is divided into two subcategories – immune 
complex SVV (which shows abundant immuno-
globulin deposition in the walls of affected vessels) 
and ANCA (antineutrophil cytoplasmic antibody)-
associated SVV (where affected vessel walls show a 
paucity of immunoglobulin deposits). Systemic 
ANCA-associated SVV includes three distinct sub-
categories: microscopic polyangiitis, granulomato-
sis with polyangiitis (previously known as Wegen-
er’s granulomatosis), and eosinophilic granulo-
matosis with polyangiitis (EGPA; previously known 
as Churg-Strauss syndrome). Interestingly, some 
patients with ANCA-associated SVV do not actually 
have detectable ANCA; it is not entirely clear 
whether that is because they have ANCA that can-
not be detected with current methods, because 
they have novel, yet-to-be discovered ANCA, or 
because pathogenesis of their vasculitis actually 
does not involve ANCA at all (Jennette et al., 2013). 
A large clinicopathologic study of EGPA-associated 
neuropathy published last year (Nishi et al., 2020) 
sheds some light on this question by providing evi-
dence for different pathogenic mechanisms in AN-
CA-positive and ANCA-negative forms of EGPA-
associated neuropathy. 
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EGPA is a form of systemic SVV that is associ-
ated with asthma, eosinophilia, and peripheral 
neuropathy; neuropathy is common and affects 50-
75% of patients. Among the three subtypes of sys-
temic ANCA-associated SVV, EGPA is least likely to 
show ANCA positivity: just 30-40% of patients have 
anti-myeloperoxidase ANCA, and almost none have 
anti-proteinase 3 ANCA (Nishi et al., 2020). To ex-
plore differences between ANCA-positive and AN-
CA-negative forms of EGPA, Nishi and co-authors 
have retrospectively investigated 82 consecutive 
patients who were diagnosed with EGPA-associated 
neuropathy and underwent sural nerve biopsy; 33% 
of study subjects were positive for anti-
myeloperoxidase ANCA and none were positive for 
anti-proteinase 3 ANCA. Clinically, ANCA-positive 
and ANCA-negative EGPA patients were quite simi-
lar, although ANCA-positive patients were more 
likely to show involvement of the upper extremities 
than the ANCA-negative ones. Pathologically, both 
ANCA-positive and ANCA-negative cases showed 
predominantly axonal form of nerve damage with a 
focal or multifocal pattern of axon loss suggestive 
of ischemic injury; however, the vascular involve-
ment differed between the two groups. Nerve bi-
opsies from ANCA-positive patients were more 
likely to show frank vasculitis and/or destruction of 
vascular structures, with the mean diameter of 
affected vessels ~170 µm (Fig. 5A); in contrast, 
nerve biopsies from ANCA-negative cases were 
more likely to show a large number of eosinophils 
in the epineurial vessel lumina, epineurial vessels 
occluded by intraluminal eosinophils (with vessels 
smaller than 13 µm typically showing more than 
50% occlusion; Fig. 5B), and extravasation of eosin-
ophils into the endoneurium. Interestingly, the 
pattern of axon loss in ANCA-negative cases 
showed no topographic correlation with the loca-
tion of endonurial eosinophils; rather, it was patchy 
(focal or multifocal), suggestive of nerve ischemia. 
Taken together, these findings suggest that there 
are two distinct pathogenetic mechanisms for is-
chemic injury in EGPA-associated neuropathy: frank 
vessel destruction in ANCA-positive cases and ves-
sel occlusion by eosinophils in ANCA-negative cases 
(the latter mechanism is conceptually similar to 
vessel occlusion by intravascular large B-cell lym-
phoma, which causes tissue ischemia without di-
rectly destroying vascular structures). While both 
patterns of vessel involvement can be seen in skel-
etal muscle (Fig. 5) in addition to peripheral nerves 
of patients with EGPA, it remains to be seen 
whether differences between ANCA-positive and 
ANCA-negative EGPA cases will be conserved across 
all affected organ systems. In addition, it needs to 
be established whether similar mechanistic differ-
ences distinguish ANCA-positive and ANCA-
negative cases in the other two types of ANCA-
associated SVV. Finally, given the almost complete 
lack of vessel wall inflammation in ANCA-negative 
EGPA cases, it needs to be re-evaluated whether 
this clinicopathologic syndrome should remain 
classified as a vasculitis or whether a different dis-
ease category would be more appropriate. 
 
 
Figure 5. Two patterns of vascular involvement in eosinophilic 
granulomatosis with polyangiitis. A. Muscle biopsy from a 
patient with ANCA-positive EGPA shows necrotizing vasculitis 
affecting small intramuscular artery; the inflammatory infil-
trate includes eosinophils. B. The lumen of a very small peri-
mysial artery (arrow) is nearly completely occluded by intralu-
minal eosinophils in a muscle biopsy from a patient with EGPA; 
ANCA status was not reported. Representative images from 
H&E-stained sections of formalin-fixed, paraffin-embedded 
tissue are shown for both cases. Scale bar, 20 µm. 
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7. Spinal muscular atrophies: Skeletal muscle 
involvement 
Spinal muscular atrophies (SMAs) are a group 
of genetic disorders in which the loss of lower mo-
tor neurons (LMNs) in the anterior horn of the spi-
nal cord, which typically occurs early in life, results 
in neurogenic muscle atrophy and weakness. The 
most common SMA subtype, 5q-SMA, accounts for 
~95% of SMA cases and is caused by autosomal 
recessive, loss-of-function mutations in both copies 
of SMN1 (survival motor neuron 1) gene; the clini-
cal phenotype is modified by the presence of the 
paralog gene, SMN2, which yields only a small 
number of full-length transcripts and is present in a 
variable number of copies in different individuals, 
with more copies resulting in a milder clinical phe-
notype and better survival. A different SMA sub-
type, known as SMALED (“spinal muscular atrophy 
lower extremity predominant”), is caused by auto-
somal dominant mutations in DYNC1H1 and BICD2 
genes, which impair centripetal microtubular 
transport that moves intracellular cargo from the 
cell periphery to the perinuclear region [DYNC1H1 
encodes a subunit of the dynamin/dynactin retro-
grade transport complex, while BICD2 encodes a 
cargo adapter protein that directly binds to 
DYNC1H1 (Koboldt et al., 2020)]. Pathogenesis of 
both 5q-SMA and SMALED was thought to involve 
loss of LMNs that occurs in a cell-autonomous 
manner; however, two studies published last year 
(Kim et al., 2020; Rossor et al., 2020) highlight the 
important and somewhat unexpected role of skele-
tal muscle in these disease processes. 
In addition to the LMN loss that is a defining 
feature of the SMA phenotype, BICD2 deficiency 
causes cerebellar hypoplasia through a pathway 
that involves Bergmann glia in a non-cell autono-
mous manner. To investigate whether the LMN loss 
in SMALED also involves non-cell autonomous 
mechanisms, Rossor et al. selectively deleted BICD2 
gene from either LMNs or skeletal muscle (Rossor 
et al., 2020). While neither mouse model showed 
altered gait or decreased life expectancy, a subtle 
loss of small diameter (gamma) motor axons was 
observed in the mice lacking BICD2 in skeletal mus-
cle; in contrast, there was no evident axon loss (or 
any other MN phenotype) in the mice lacking BICD2 
expression in LMNs. Further experiments demon-
strated that skeletal muscle from Bicd2-/- mice 
showed a reduction in the number of muscle spin-
dles but no neurogenic changes indicative of the 
loss of alpha LMNs; similar findings were seen in 
mice lacking DYNC1H1. Finally, the authors used an 
in vitro assay to show a decreased secretory activity 
in fibroblasts from a SMALED patient with a BICD2 
mutation when compared to fibroblasts from a 
control patient. Based on these findings, Rossor et 
al. proposed that the LMN loss in SMALED is non-
cell autonomous and involves reduced neurotro-
phin secretion from skeletal muscle, which limits 
neurotrophin availability and leads to excess LMN 
apoptosis during development. While this hypothe-
sis is intriguing, it is currently not clear whether a 
similar pathogenetic mechanism operates in hu-
man disease; in particular, biopsies from SMALED 
patients show a mixture of neurogenic and myopa-
thic changes that is not well replicated by the exist-
ing mouse models. In addition, it is not clear why 
diminished neurotrophin availability would prefer-
entially affect LMNs that innervate lower extremi-
ties. Nonetheless, the results of this study are suffi-
ciently compelling to warrant further investigation. 
Kim et al. have used a similar experimental 
approach to explore the role of skeletal muscle in 
the 5q-SMA pathogenesis (Kim et al., 2020). Intri-
guingly, they found that the lack of SMN expression 
in skeletal muscle results in an age-dependent my-
opathy that is usually obscured by the concurrent 
neurogenic process driven by the LMN loss. In the 
presence of a single copy of SMN2 gene, SMN1 
deficiency in skeletal muscle led to an early-onset 
myopathy and severely shortened life span, with 
most mice dying by the postnatal day 25. A milder 
phenotype was seen in mice deficient for SMN1 
that carried two copies of SNM2 gene: at a young 
age, their skeletal muscles appeared normal but 
showed impaired regeneration following a myotox-
ic insult; by 6-7 months of age, outright myopathic 
changes and impaired functional muscle perfor-
mance were observed, leading to early mortality 
with only 14% of mutants (but 95% of controls) 
viable at 18 months. Importantly, restoration of 
muscle SMN levels in 7-month-old mice mitigated 
the observed muscle pathology. Conceptually, this 
study reinforces the paradigm observed with many 
genetic diseases: a treatment that is effective but 
targets only the most severely affected organ sys-
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tem typically unmasks the effects of the same mu-
tation on other organ systems that were previously 
not apparent, but now need to be addressed. For 
patients with 5q-SMA, the implications are more 
practical: nusinersen treatment, which is given 
intrathecally and therefore increases SMN expres-
sion in the spinal cord but not in skeletal muscle, 
may need to be combined with (or replaced by) a 
treatment that also increases SMN levels in periph-
eral tissues; one candidate for such therapy is 
AAV9-SMN, an AAV9 (adeno-associated virus 9) 
vector carrying human SMN transgene that was 
approved for 5q-SMA treatment in 2019, but is 
currently restricted to patients younger than 2 
years of age [for more information on emerging 
treatments for 5q-SMA, see the prior update in this 
article series (Margeta, 2020b)]. Additional clinical 
trials that specifically focus on myopathic pathology 
in 5q-SMA will be needed to address this clinically 
important issue. Moreover, it will be important to 
determine how SMN deficiency leads to the failure 
of muscle maintenance, which seems to underpin 
this late-onset muscle pathology. 
8. Idiopathic inflammatory myopathies: The role 
of autoantibodies targeting sarcolemmal repair 
proteins 
Based on the current clinicoseropathologic cri-
teria, idiopathic inflammatory myopathies (IIMs) 
are divided into four distinct subcategories [derma-
tomyositis (DM), anti-synthetase syndrome-
associated myositis (ASM), immune-mediated ne-
crotizing myopathy (IMNM), and sporadic inclusion 
body myositis (sIBM); for a brief overview of the 
diagnostic criteria and other recent advances in the 
IIM field, see last year’s update in this article series 
(Margeta, 2020b)]. IIM pathogenesis is complex 
and only partly understood, but an interesting 
study published last year uncovered a feed-forward 
mechanism that contributes to IIM progression by 
linking development of autoantibodies against 
TRIM72 (also known as mitsugumin 53) with defec-
tive sarcolemmal repair and ongoing exposure of 
intracellular autoantigens (McElhanon et al., 2020). 
TRIM72 is a 53 kDa member of the TRIM fami-
ly of proteins; it is highly expressed in striated mus-
cle and has many different cellular functions, in-
cluding a key role in the plasma membrane repair. 
Following sarcolemmal injury, TRIM72 nucleates 
and then coats intracellular lipid vesicles that ac-
cumulate at the site of the membrane break; fusion 
of these vesicles with damaged sarcolemma cre-
ates a “patch” that seals the membrane defect in a 
process that requires Ca2+ as well as interaction of 
TRIM72 with dysferlin and caveolin 3 (reviewed in 
Benissan-Messan et al., 2020). While mutations in 
dysferlin and caveolin 3 lead to limb-girdle muscu-
lar dystrophies 2B and 1C, respectively, mutations 
in TRIM72 have not yet been linked to any human 
disease; however, the myocardium of TRIM72-
deficient mice is more vulnerable to ischemia (Cao 
et al., 2010), highlighting the importance of this 
protein for striated muscle integrity. 
Building on that body of work, McElhanon et 
al. have now implicated TRIM72 in the IIM patho-
genesis by using an adaptive transfer animal model 
of IIM. In this model, lymph node cells from Syt7-/- 
FoxP3-/γ double mutant mice (which have defective 
membrane repair and are prone to autoimmunity 
because they lack Tregs) are transferred into im-
munologically naïve Rag1-/- mice, who one week 
after transfer develop an inflammatory myopathy. 
Intriguingly, endomysial inflammatory infiltrates 
composed of T cells and macrophages were present 
only in the proximal muscles of the recipient mice, 
while “leaky” muscle fibers with compromised sar-
colemma were identified in both proximal and dis-
tal muscles. The presence of myofiber damage in 
non-inflamed distal muscles raised the possibility 
that humoral rather than cellular autoimmunity 
caused impaired sarcolemmal repair in this mouse 
model, leading the authors to investigate whether 
the recipient mice developed autoantibodies 
against one or more proteins involved in this pro-
cess. Indeed, anti-TRIM72 autoantibodies were 
detectable in the sera of the recipient mice as well 
as in 10-30% (depending on the chosen cutoff) of 
sera from 103 human IIM patients. Importantly, the 
authors showed that anti-TRIM72 antibodies were 
pathogenic: treatment of isolated normal muscle 
fibers by either purified anti-TRIM72 antibodies or 
by human IIM sera positive for these antibodies 
caused a membrane repair defect (as measured by 
an in vitro membrane resealing assay), while deple-
tion of anti-TRIM72 antibodies from human IIM 
sera strongly attenuated this effect. Based on these 
findings, the authors proposed a new model of IIM 
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pathogenesis, in which sarcolemmal disruption 
caused by any number of events (including a viral 
or bacterial infection, trauma, or overexertion) 
results in exposure of sarcolemmal repair proteins 
to the immune system; in susceptible individuals, 
this exposure leads to development of autoanti-
bodies that target TRIM72 and/or other repair pro-
teins, compromising membrane resealing and lead-
ing to continuous autoantigen exposure in a feed-
forward loop. While this model needs to be exper-
imentally tested, it does provide possible explana-
tion for association of COVID-19 (and other viral 
illnesses) with immune-mediated muscle pathology 
(discussed in advance #3). 
One limitation of this otherwise very nicely 
done study is the outdated classification of the 
patient IIM sera used for experiments (they were 
classified into DM and polymyositis categories, 
presumably because they were obtained from a 
specimen bank that performed specimen collection 
before introduction of the current IIM diagnostic 
criteria). Nevertheless, the study included infor-
mation about the status of a subset of myositis-
specific antibodies in the same IIM specimen set, 
providing at least partial clues to more up-to-date 
classification. Based on this limited information, 
anti-TRIM72 antibodies were present in a signifi-
cant fraction of IIM patients with DM-associated 
antibodies (anti-Mi-2, anti-TIF1γ, and anti-SEA), as 
well as one of two patients with IMNM-associated 
anti-SRP antibodies; in contrast, they were not de-
tected in any of patients with the ASM-associated 
anti-Jo-1 antibodies. While these findings need to 
be replicated and extended by evaluation of pa-
tients from all currently defined IIM subcategories 
(including sIBM and other subtypes of IMNM), they 
do raise the possibility that this new pathomecha-
nism plays a bigger role in pathogenesis of DM and 
IMNM than ASM. In that context, it is intriguing 
that TIF1γ / TRIM33 – which is targeted by one of 
the DM-associated myositis-specific antibodies – is 
another member of the TRIM protein family, alt-
hough in contrast to TRIM72 it does not seem to 
play a significant role in skeletal muscle repair 
(Parks et al., 2019). 
 
Advances in neuromuscular disease 
diagnostics 
9. Large-scale electron microscopy 
Transmission electron microscopy (TEM) re-
mains an important diagnostic tool in the contem-
porary neuromuscular pathology workflow, but 
some practical limitations diminish its potential 
usefulness. In particular, it is typically necessary to 
maximize the use of these expensive instruments 
while minimizing the number of people who must 
obtain specialized training required to operate 
them; as a result, diagnostic ultrastructural evalua-
tion is typically performed on static images of se-
lect areas of interest that were previously captured 
by the trained laboratory staff. While reasonably 
effective, this approach makes it challenging to 
relate the captured nanoscale images to the mi-
croscale tissue architecture appreciated by light 
microscopy; in addition, depending on the staff 
expertise level, there is always a possibility that the 
captured images are not fully representative of the 
underlying pathology, leading to diagnostic errors. 
To circumvent some of these limitations, large-
scale EM [also known as “virtual EM” or nanotomy 
(short for nanometer-scale anatomy)] has been 
developed over the last decade; while the first use 
of this technique in the NMD field was reported in 
2003 (Sullivan et al., 2003), a wider adoption did 
not happen until last year (Dittmayer et al., 2020b; 
Dittmayer et al., 2020c; Rocha et al., 2020). 
In large-scale EM, the entire ultrathin sections 
are digitized by automated acquisition of multiple 
overlapping image tiles that are then stitched into a 
single large image; the resulting high-resolution 
digital images can then be evaluated on a standard 
computer workstation, enabling easy navigation 
between micrometer and nanometer scales across 
the entire ultrathin section. Initial applications of 
this technology were based on stitching of multiple 
traditionally acquired TEM images (Sullivan et al., 
2003; Faas et al., 2012; Lee and Mak, 2011); while 
providing a proof-of-principle for virtual EM as a 
diagnostic and research tool, this approach had two 
major limitations - (1) imperfect image quality due 
to interference from the specimen support grids 
and various preparation flaws, and (2) a long time 
required to capture and stich a very large number 
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of standard TEM images. In the years that followed, 
these limitations were addressed by replacing tra-
ditional TEM by field-emission scanning EM 
(FESEM); one FESEM image captures the field of 
view that is equivalent to ~100 TEM images, thus 
significantly reducing the amount of required im-
age stitching and accelerating the entire process 
(Kuipers et al., 2016). In FESEM, imaging of ul-
trathin sections can be performed using a conduc-
tive silicon substrate that does not cause any visual 
interference, producing very sharp TEM-like images 
through detection of backscattered electrons 
(Dittmayer et al., 2018); this solves problem 1, but 
not entirely problem 2 because imaging speed re-
mains slow (Kuipers et al., 2016). Alternatively, 
FESEM can be used for digitization of sections pre-
pared with conventional TEM slot grids and imaged 
in a transmission mode with a scanning transmis-
sion electron microscopy (STEM) detector (Kuipers 
et al., 2016); this solves problem 2 due to faster 
imaging, but preparation of samples with minimal 
flaws remains challenging. Despite remaining limi-
tations, the capabilities of this new technology are 
already impressive: if STEM is combined with con-
ventional modern systems, automated digitization 
of entire ultrathin sections at a 7 nm-pixel resolu-
tion can be performed in about 12 h (Dittmayer et 
al., 2020c), while specialized high-throughput imag-
ing systems based on FESEM and TEM technology 
can reduce the imaging time to about 10-20 min. 
 
 
Figure 6. Transthyretin amyloid deposition in a peripheral nerve and skeletal muscle of a patient with ATTRv. Sural nerve biopsy (A-D) 
shows accumulation of Congo red-positive amyloid substance in the arterial walls (A); the deposits demonstrate apple-green birefrin-
gence under the polarized light (B) and are immunoreactive with anti-transthyretin antibody (C). Marked loss of myelinated axons is 
evident on Toluidine blue stain (D). Sections from a gastrocnemius muscle biopsy (E-J) show deposition of TTR amyloid in the arterial 
walls (E-G) and fiber sarcoplasm (H-J); well-developed neurogenic changes were also present (not shown). Subsequent to the biopsy 
diagnosis of TTR amyloid neuropathy and myopathy, the patient was found to carry a pathogenic TTR p.Phe84Leu mutation and was 
diagnosed with ATTRv; he was treated by inotersen and initially stabilized, but then continued to progress and will likely be switched to 
the patisiran therapy going forward. Panels A-C and E-J, formalin-fixed, paraffin embedded tissue; panel D, Epon-embedded tissue. 
Panels A-B, E-F, and H-I, Congo red stain; panels C, G and J, transthyretin immunoperoxidase stain; panel D, Toluidine blue stain. Scale 
bars, 50 µm. 
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When will large-scale EM become available for 
routine diagnostic use? That is difficult to predict, 
given that the most sophisticated version of the 
technique requires purchase of new, more ad-
vanced EM instruments; however, the cost could 
be justified by anticipated improvements in diag-
nostic accuracy, opportunities for digital pathology 
research, and reduction in the time spent on image 
acquisition by the laboratory staff. In the mean-
time, one can get a taste of this exciting new tech-
nology by viewing open-source datasets available 
at http://www.nanotomy.org/  
Advances in neuromuscular disease 
treatment  
10. Long-term efficacy and safety: Gene-
silencing therapies for transthyretin amyloid 
neuropathy 
Transthyretin amyloidosis (ATTR) is caused by 
deposition of either wild-type or mutant transthy-
retin (TTR) in different tissues throughout the body; 
these two disease forms are referred to as ATTRwt 
and ATTRv (“v” for variant), respectively. TTR func-
tions as a carrier for thyroxin and retinol/vitamin A 
and is primarily synthetized by the liver; clinical 
symptoms of ATTR are largely due to accumulation 
of TTR amyloid in the heart and peripheral nerves, 
but skeletal muscle can also be affected in rare 
cases (Fig. 6 and Pinto et al., 2020; see also Fig. 1 in 
Lam et al., 2015). Interestingly, recent work has 
shown that tissue damage in ATTR is caused not 
only by the amyloid fibril deposition but also by 
toxicity of nonfibrillar transthyretin oligomers, 
which directly damage endothelial cells and nerve 
fibers (reviewed in Koike and Katsuno, 2020). 
Fully assembled TTR is a conformationally sta-
ble homotetramer; in contrast, individual TTR 
monomers are prone to misfolding and aggrega-
tion. Thus, the currently approved ATTRv therapies 
aim either to stabilize the tetrameric quaternary 
structure of TTR (tafimidis or diflunisal; approved in 
the early 2010s) or to inhibit TTR synthesis through 
gene silencing approaches (inotersen or patisiran; 
both approved in 2018). Untreated ATTRv is a rap-
idly progressive disease with a poor prognosis, and 
the availability of several disease-modifying treat-
ments was an incredible breakthrough for the NMD 
field. At the same time, many important treatment-
related questions remained open, and had to be 
addressed through post-approval studies. For ex-
ample, at the time of approval little was known 
about the long-term efficacy and safety of TTR-
silencing drugs. In addition, it was not clear how 
different ATTRv treatment options compare to 
each other. While much work still remains to be 
done, at least some of these questions have been 
decisively answered by studies published in 2020. 
Inotersen is an antisense oligonucleotide that 
inhibits TTR production and thereby slows the pro-
gression of ATTRv polyneuropathy; based on a 2-
year update from the open-label extension of the 
NEURO-TTR clinical trial (which led to its initial ap-
proval), no new safety concerns were identified 
and the drug continued to demonstrate therapeu-
tic benefits. However, the outcomes were signifi-
cantly better in study subjects who were originally 
placed in the experimental arm than in those who 
were originally in the placebo arm, indicating that 
early treatment is critical for inotersen efficacy 
(Brannagan et al., 2020). Similar results were seen 
with patisiran, which is an RNA-interference thera-
peutic that also inhibits TTR synthesis; a 12-month 
update from the open-label extension of the APOL-
LO clinical trial (which led to initial approval of this 
drug) also demonstrated no new safety concerns 
and continued efficacy, with sustained benefit in 
patients who were originally part of the patisiran 
arm and a new improvement in patients who were 
originally part of the placebo arm. Interestingly, the 
frequency of deaths was higher in the initial place-
bo group than in the initial patisiran group, again 
highlighting the benefits of early treatment (Adams 
et al., 2021). Finally, an indirect comparison of the 
data from NEURO-TTR and APOLLO clinical trials 
demonstrated that patisiran was generally more 
effective than inotersen, with a greater treatment 
benefit observed on all polyneuropathy and quality 
of life measures evaluated by both trials (Gorevic et 
al., 2021). Taken together with a prior study that 
showed a greater efficacy of inotersen compared to 
tafimidis in patients with ATTRv polyneuropathy 
(Plante-Bordeneuve et al., 2019), these data sug-
gest that patisiran is the best currently available 
treatment for ATTRv polyneuropathy. It needs to 
be noted that both these indirect comparison stud-
ies were funded by Alnylam Pharmaceuticals, the 
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manufacturer of patisiran; however, given the 
magnitude and robustness of the observed thera-
peutic differences, it is unlikely that the results 
were significantly confounded by the sponsor’s 
financial interests. 
Despite these advances, a lot remains to be 
explored. For example, it needs to be established 
whether TTR-silencing therapies will also be effec-
tive for treatment of ATTRwt polyneuropathy, and - 
if they are - whether their therapeutic benefit will 
be superior to that of tafimidis (which has been 
approved for ATTRwt treatment). Similarly, both 
TTR-silencing drugs still need to be evaluated as 
treatments for ATTRv (and ATTRwt) cardiomyopa-
thy: initial exploratory studies showed that in-
otersen led to no improvement in cardiac function 
while patisiran stopped (and even reversed) the 
progression of cardiac disease in ATTRv patients 
(reviewed in Adams and Slama, 2020), but random-
ized clinical trials addressing the cardiac aspect of 
ATTR still need to be done. 
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